Mr. Hugh MacNaught reports

VENTRIPOINT ANNOUNCES EXTENSION OF PRIVATE PLACEMENT OFFERINGS AND UPSIZE OF NON-BROKERED PRIVATE PLACEMENT PURSUANT TO LISTED ISSUER FINANCING EXEMPTION

Ventripoint Diagnostics Ltd. has received approval of TSX Venture Exchange to extend its previously announced non-brokered private placements of up to $3-million of unsecured convertible debentures and up to $500,000 (the listed issuer financing exemption offering) of units of the corporation at a price of 19.5 cents per unit for a further 30 days, and has further upsized the LIFE offering to $700,000 (see press releases dated Aug. 28, 2024, Aug. 29, 2024, Sept. 17, 2024, and Sept. 20, 2024).

There is an offering document related to the LIFE offering that can be viewed under the company's profile at SEDAR+ and on the company's website. Prospective investors should read this offering document before making an investment decision.

The outside date for closing both CD offering and the LIFE offering has been extended from Oct. 12, 2024, to Nov. 12, 2024. The CD offering and the LIFE offering remain subject to certain conditions, including, but not limited to, receipt of all necessary approvals, including approval of TSX-V.

The corporation will use the proceeds of the offering to finance operational costs related to sales and marketing, additional key personnel, and general working capital purposes.

About Ventripoint Diagnostics Ltd.

Ventripoint has become an industry leader in the application of AI (artificial intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary knowledge-based reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide its future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the United States, Europe and Canada.

We seek Safe Harbor.